Omega Funds

Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund

Retrieved on: 
Thursday, October 14, 2021
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Scripps Research, The Programme, Degenerative disease, Disease, POC, Partner, Gastrointestinal tract, Therapy, Medication, Pharma, EIF, DVI, Marshall Plan, Precision medicine, Health, Patient, ERP, Biotechnology, Computational biology, Partner (business rank), ABC, BGV, Drug discovery, Alnylam Pharmaceuticals, EUR, Vertex Pharmaceuticals, European Recovery Plan, Liver, Senior, Socially responsible investing, CBO, Department, PFM Group, Eye, Investment, Executive, Central nervous system, Vertex, CFTR, Growth, Atlas, Atlas Venture, EFSI, LFA, Cystic fibrosis, Lists of diseases, Institute of Liver and Biliary Sciences, Company, Omega, Entrepreneurship, United Nations Principles of Medical Ethics, Pharmaceutical industry, Management, Aquaculture, Fine chemical, Rectify Pharmaceuticals, Inc. (“Rectify”), Atlas Venture, Omega Funds, Forbion, Longwood Fund, RECTIFY PHARMACEUTICALS, INC. (“RECTIFY”), ATLAS VENTURE, OMEGA FUNDS, FORBION, LONGWOOD FUND

Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.

Key Points: 
  • Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.
  • Rectify plans to use this financing to fund the company through its first human proof-of-concept (POC) studies.
  • We founded Rectify to deliver life-changing therapies to patients with serious genetic diseases, said Rajesh Devraj, Ph.D., President and Chief Executive Officer and venture partner with Atlas Venture.
  • Jonathan Moore, Ph.D., Chief Scientific Officer, founded Rectify with Atlas Venture in 2020.

Artios raises $153m in Series C financing

Retrieved on: 
Tuesday, July 27, 2021
TCG, Artios Pharma Limited, Omega Funds, TCG X, ARTIOS PHARMA LIMITED, OMEGA FUNDS, TCG X

The oversubscribed financing was co-led by Omega Funds and TCG X.

Key Points: 
  • The oversubscribed financing was co-led by Omega Funds and TCG X.
  • In connection with the close of the Series C financing, Michelle Doig, Partner, Head of Corporate Development, Omega Funds and Chen Yu, Founding Managing Partner, TCG X, will join Artios' Board of Directors.
  • By investing in this financing round we are creating multiple avenues of value creation for our funds' investors."
  • This financing follows an $84 million (65 million) Series B fundraise concluded in August 2018 and yields total capital raised to date from investors and strategic partners of more than US$320 million.

Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds

Retrieved on: 
Tuesday, January 5, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Biomarkers, Biology, Life sciences, Biotechnology, Chemical pathology, KRAS, Omega Funds, Ikena Oncology

Ikena Oncology, Inc. (Ikena), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing.

Key Points: 
  • Ikena Oncology, Inc. (Ikena), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing.
  • Ikena intends to use the proceeds from this financing to advance its pipeline of targeted oncology therapies, including its novel development candidate TEAD inhibitor IK-930, and a new first-in-class preclinical program targeting KRAS signaling.
  • In connection with this financing, Otello Stampacchia, Ph.D., Managing Director of Omega Funds, will join Ikenas Board of Directors.
  • Omega Funds' portfolio companies have brought 37 products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others.

Alpine Immune Sciences Announces $60 Million Private Placement

Retrieved on: 
Friday, July 24, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Clinical medicine, Virotherapy, Medicine, Cancer immunotherapy, Immunotherapy, Health care, Alpine Immune Sciences, Inc., Omega Funds

The team at Alpine is passionate about solving complex problems in immuno-oncology and autoimmune disease to create innovative and meaningful therapies for patients, said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine Immune Sciences.

Key Points: 
  • The team at Alpine is passionate about solving complex problems in immuno-oncology and autoimmune disease to create innovative and meaningful therapies for patients, said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine Immune Sciences.
  • Additional details regarding the private placement will be included in a Form 8-K to be filed by Alpine with the Securities and Exchange Commission (SEC).
  • Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients lives via unique protein engineering technologies.
  • The Alpine logo is a registered trademark or trademark of Alpine Immune Sciences, Inc. in various jurisdictions.

Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth

Retrieved on: 
Thursday, February 20, 2020
Biotechnology, General Health, Pharmaceutical, Health, Abingworth, Biotechnology, Classic Congenital Adrenal Hyperplasia (CAH), Tildacerfont, Spruce Biosciences, Omega Funds, Abingworth

This drug could be a life-altering therapy for patients with CAH, said Dina Chaya, Advisor to Omega Funds.

Key Points: 
  • This drug could be a life-altering therapy for patients with CAH, said Dina Chaya, Advisor to Omega Funds.
  • Spruce Biosciences is a clinical-stage biotechnology company focused on developing and commercializing novel therapies for rare endocrine disorders.
  • Since 1973, Abingworth has invested in approximately 160 life science companies, leading to more than 40 M&A/exits and over 65 IPOs.
  • Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California) and Boston.